Institutional Biosafety Committee (IBC)

The Weill Cornell Medical College IBC's primary responsibility is to work with the WCMC research community to ensure that recombinant and synthetic nucleic acid molecule (including transgenic animal and human gene transfer) research conducted at WCMC is carried out in accordance with the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules.

The IBC also reviews non-recombinant or synthetic nucleic acid research involving agents classified as Risk Group 2, 3, and 4 in the NIH Guidelines, Appendix B, non-recombinant DNA research involving select agents as listed by the CDC (Right-click and choose "Save Link As" to view), and research involving the use of biological agents in human subjects research. "Biological Agents" should be taken to mean non-FDA approved viruses, bacteria and other etiological agents that are used as Investigational New Drugs (INDs)/vaccines in human subjects.

WCMC IBC meetings are open to the public. WCMC reserves the right to hold executive sessions during IBC meetings. Executive sessions are not open to the public.